Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
|Articles|November 1, 1996
Oncology NEWS International
- Oncology NEWS International Vol 5 No 11
- Volume 5
- Issue 11
FDA Approves Xillix LIFE-Lung System
ROCKVILLE, Md-The FDA has given final approval to the Xillix LIFE-Lung Fluorescence Endoscopy System for use in detecting early lung cancer. Xillix Technologies Corp., of Richmond, British Columbia, plans to market the system worldwide in early 1997.
Advertisement
ROCKVILLE, MdThe FDA has given final approval to the Xillix LIFE-Lung Fluorescence Endoscopy System for use in detecting early lung cancer. Xillix Technologies Corp., of Richmond, British Columbia, plans to market the system worldwide in early 1997.
Articles in this issue
almost 30 years ago
Factor Analysis of New Symptom Scale in Breast Cancer Finds Six Clustersabout 30 years ago
AIDS Funding Increased for Fiscal '97about 30 years ago
'Cancer Rates and Risks' Availableabout 30 years ago
New Breast Cancer Patient Resource Is Availableabout 30 years ago
Short-Term Metronidazole not Linked to Cancerabout 30 years ago
Various Capitation Models Are Available for Oncology Networksabout 30 years ago
NCI Urges full Disclosure of Cigarette Contentsabout 30 years ago
Antifungal Resistance on the Increaseabout 30 years ago
Fentanyl Patch Useful Alternative in Cancer Pain Patientsabout 30 years ago
Analysis of Microvessel Density Predicts Extraprostatic SpreadAdvertisement
Related to this article
Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5